Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
Eligibility Criteria
- * Any patients with suspected (clinical) or definitive (tissue) diagnosis of Stage III-IV melanoma starting or continuing adjuvant Pembrolizumab without active evidence of disease (NED).
- * Must be treatment naïve or have had treatment no less than 6 months prior to enrollment
- * 18 years or older
- * Must be able to take pills
- * ECOG performance status of 0-3
- * Ability to understand and willingness to sign a written informed consent
- * Members of all racial and ethnic groups are eligible for this study
- * History of hypersensitivity reactions attributed to beta-glucan
- * Patients receiving continuous or other ongoing immunosuppressive therapy
- * Uncontrolled intercurrent illness including, but not limited to, autoimmune diseases, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- * Any patients who have serious autoimmune toxicity during the study period, or those who have disease recurrence during the 6-week study period should be excluded and analyzed separately
- * Patients with mucosal melanoma
- * Patients with concurrent malignancy or recent history thereof
Ages Eligible for Study
18 Years to
Sexes Eligible for Study
ALL
Accepts Healthy Volunteers
No